For Fourth Quarter 2018, Zoetis Reports Revenue of $1.6 Billion, Growing 7%, and Net Income of $345 Million, or $0.71 per
- For Fourth Quarter 2018, Zoetis Reports Revenue of $1.6 Billion, Growing 7%, and Net Income of $345 Million, or $0.71 per Diluted Share, on a Reported Basis
- Reports Adjusted Net Income of $382 Million, or Adjusted Diluted EPS of $0.79, for Fourth Quarter 2018
- Delivers 11% Operational Growth in Revenue and 21% Operational Growth in Adjusted Net Income for Fourth Quarter 2018
- For Full Year 2018, Zoetis Reports Revenue of $5.8 Billion, Growing 10%, and Net Income of $1.4 Billion, or $2.93 per Diluted Share, on a Reported Basis
- Reports Adjusted Net Income of $1.5 Billion, or Adjusted Diluted EPS of $3.13, for Full Year 2018
- Delivers 10% Operational Growth in Revenue and 31% Operational Growth in Adjusted Net Income for Full Year 2018
- Provides Full Year 2019 Revenue Guidance of $6.175 - $6.300 Billion, with Diluted EPS of $2.83 - $2.99 on a Reported Basis, or $3.42 - $3.52 on an Adjusted Basis
PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2018 and provided full year guidance for 2019. Financial results for the quarter and year include the impact of the acquisition of Abaxis.
The company reported revenue of $1.6 billion for the fourth quarter of 2018, which was an increase of 7% compared with the fourth quarter of 2017. Net income for the fourth quarter of 2018 was $345 million, or $0.71 per diluted share, compared with $81 million, or $0.16 per diluted share, in the fourth quarter of 2017.
Adjusted net income1 for the fourth quarter of 2018 was $382 million, or $0.79 per diluted share, an increase of 12% and 14%, respectively. Adjusted net income for the fourth quarter of 2018 excludes the net impact of $37 million for purchase accounting adjustments, acquisition-related costs and certain significant items.
On an operational2 basis, revenue for the fourth quarter of 2018, excluding the impact of foreign exchange, increased 11% compared with the fourth quarter of 2017. Adjusted net income for the fourth quarter of 2018 increased 21% operationally, excluding the impact of foreign exchange.
For full year 2018, the company reported revenue of $5.8 billion, an increase of 10% compared with full year 2017. Net income for full year 2018 was $1.4 billion, or $2.93 per diluted share, an increase of 65% and 67%, respectively.
Adjusted net income for full year 2018 was $1.5 billion, or $3.13 per diluted share, an increase of 29% and 30%, respectively. Adjusted net income for full year 2018 excludes the net impact of $97 million for purchase accounting adjustments, acquisition-related costs and certain significant items.
On an operational basis, revenue for full year 2018 increased 10%, excluding the impact of foreign exchange. Adjusted net income for full year 2018 increased 31% operationally, excluding the impact of foreign exchange.
EXECUTIVE COMMENTARY
“Zoetis delivered another year of strong performance in 2018 and executed on investment plans that continue to strengthen our product portfolio across the continuum of care,” said Juan Ramón Alaix, Chief Executive Officer of Zoetis. “We achieved operational revenue growth for the year of 10%, growing revenue across all of our core species, major markets and therapeutic areas. We also grew our adjusted net income faster than sales, at 31% operationally, as we continue to deliver on our long-term value proposition.”
“Looking ahead, we will continue to build on our strategic investment plans to support the growth of our core business, and in evolving spaces such as diagnostics, devices, digital and data analytics. For full year 2019, we expect operational growth of 7.5% to 9.5% in revenue and 8% to 11% in adjusted net income. We remain committed to funding investments that will help us maintain our leadership and growth, while returning excess capital to shareholders.”
QUARTERLY HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two regional segments: the United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for livestock and companion animals tailored to local trends and customer needs. In the fourth quarter of 2018:
- Revenue in the U.S. segment was $809 million, an increase of 14% compared with the fourth quarter of 2017. Sales of companion animal products grew 26% driven primarily by the acquisition of Abaxis, our key dermatology portfolio, and new products, including Simparica®. Growth in our companion animal business was partially offset by lower sales of certain in-line products due to anticipated competition. Sales of livestock products grew 3% in the quarter with all species contributing to growth. Growth in our cattle business was primarily due to higher sales of premium products, as well as competitor supply constraints. Poultry business growth was largely due to increased sales of alternatives to antibiotic medicated feed additives, while our swine business growth was the result of promotional efforts that drove increased demand across our therapeutic portfolio.
- Revenue in the International segment was $727 million, a decrease of 2% on a reported basis and an increase of 5% operationally compared with the fourth quarter of 2017. Sales of companion animal products grew 7% on a reported basis and 14% on an operational basis. Growth resulted primarily from the acquisition of Abaxis, parasiticides (Simparica for dogs and Stronghold® Plus for cats), and increased sales across our key dermatology portfolio. Sales of livestock products declined 6% on a reported basis and grew 2% operationally; poultry, swine and fish all exhibited growth, while cattle was relatively flat in the quarter. Increased revenue in poultry products was the result of solid performance in other emerging markets, including Egypt and Indonesia. Growth in our swine business was largely driven by the recently launched Suvaxyn® PCV combo and PRRS vaccines in Europe, as well as strong demand for our products in other emerging markets. Our fish business grew due to market share gains of our PD vaccines in both the UK and Norway, as well as the continued growth of our LiVac® SRS vaccine in Chile.
Zoetis continues to drive demand and strengthen its diverse portfolio through product lifecycle innovations, as well as expansion of key products into new geographies. Since our last quarterly earnings announcement:
- Zoetis received approval in the U.S. and Canada for Revolution® Plus (selamectin and sarolaner topical solution), a new combination topical product for cats and kittens that provides parasite protection against fleas, ticks, ear mites, roundworms, hookworms and heartworms. Revolution Plus combines the proven broad-spectrum protection of selamectin with the advanced flea- and tick-killing power of sarolaner. This first-of-its-kind product exemplifies Zoetis’ dedication to innovation in parasiticides and builds on the 20-year trusted legacy of feline Revolution.
- The company also continued to bring its newest leading canine products to additional markets. Cytopoint® (lokivetmab), a monoclonal antibody that is part of Zoetis’ canine dermatology portfolio, and Simparica, an oral flea and tick medication for dogs, both received additional approvals in countries in Asia and the Middle East.
FINANCIAL GUIDANCE
Zoetis is providing full year 2019 guidance, which includes:
- Revenue between $6.175 billion to $6.300 billion
- Reported diluted EPS between $2.83 to $2.99
- Adjusted diluted EPS between $3.42 to $3.52
This guidance reflects foreign exchange rates as of late January. Additional details on guidance are included in the financial tables and will be discussed on the company’s conference call this morning.
WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2018 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on Feb. 14, 2019.
About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit www.zoetis.com.
1 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.
2 Operational revenue growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, expectations regarding the performance of acquired companies and our ability to integrate new businesses, expectations regarding the financial impact of acquisitions, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.
Internet Posting of Information: We routinely post information that may be important to investors in the ‘Investors’ section of our website at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us.
| ZOETIS INC. CONSOLIDATED STATEMENTS OF INCOME(a) (UNAUDITED) (millions of dollars, except per share data) | ||||||||||||||||||||||||||
| Fourth Quarter | Full Year | |||||||||||||||||||||||||
| 2018 | 2017 | % Change | 2018 | 2017 | % Change | |||||||||||||||||||||
| Revenue | $ | 1,564 | $ | 1,460 | 7 | $ | 5,825 | $ | 5,307 | 10 | ||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||||||||
| Cost of sales(b) | 544 | 457 | 19 | 1,911 | 1,775 | 8 | ||||||||||||||||||||
| Selling, general and administrative expenses(b) | 420 | 361 | 16 | 1,484 | 1,334 | 11 | ||||||||||||||||||||
| Research and development expenses(b) | 125 | 110 | 14 | 432 | 382 | 13 | ||||||||||||||||||||
| Amortization of intangible assets(c) | 39 | 23 | 70 | 117 | 91 | 29 | ||||||||||||||||||||
| Restructuring charges and certain acquisition-related costs | 14 | 12 | 17 | 68 | 19 | * | ||||||||||||||||||||
| Interest expense | 59 | 50 | 18 | 206 | 175 | 18 | ||||||||||||||||||||
| Other (income)/deductions–net | (55 | ) | 17 | * | (83 | ) | 6 | * | ||||||||||||||||||
| Income before provision for taxes on income | 418 | 430 | (3) | 1,690 | 1,525 | 11 | ||||||||||||||||||||
| Provision for taxes on income | 73 | 350 | (79) | 266 | 663 | (60) | ||||||||||||||||||||
| Net income before allocation to noncontrolling interests | 345 | 80 | * | 1,424 | 862 | 65 | ||||||||||||||||||||
| Less: Net (loss)/income attributable to noncontrolling interests | — | (1 | ) | (100) | (4 | ) | (2 | ) | 100 | |||||||||||||||||
| Net income attributable to Zoetis | $ | 345 | $ | 81 | * | $ | 1,428 | $ | 864 | 65 | ||||||||||||||||
| Earnings per share—basic | $ | 0.72 | $ | 0.17 | * | $ | 2.96 | $ | 1.76 | 68 | ||||||||||||||||
| Earnings per share—diluted | $ | 0.71 | $ | 0.16 | * | $ | 2.93 | $ | 1.75 | 67 | ||||||||||||||||
| Weighted-average shares used to calculate earnings per share (in thousands) | ||||||||||||||||||||||||||
| Basic | 480,603 | 487,323 | 483,063 | 489,918 | ||||||||||||||||||||||
| Diluted | 484,479 | 491,022 | 486,898 | 493,161 | ||||||||||||||||||||||
| * Calculation not meaningful. |
| Certain amounts and percentages may reflect rounding adjustments. |
| (a) The consolidated statements of income present the three and twelve months ended December 31, 2018 and 2017. Subsidiaries operating outside the United States |
| (b) Exclusive of amortization of intangible assets, except as discussed in footnote (c) below. |
| (c) Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, |
| ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data) | |||||||||||||||||||||||||
| Quarter Ended December 31, 2018 | |||||||||||||||||||||||||
| GAAP | Purchase | Acquisition- | Certain | Non-GAAP | |||||||||||||||||||||
| Cost of sales(c) | $ | 544 | $ | (14 | ) | $ | — | $ | (4 | ) | $ | 526 | |||||||||||||
| Gross profit | 1,020 | 14 | — | 4 | 1,038 | ||||||||||||||||||||
| Selling, general and administrative expenses(c) | 420 | (18 | ) | — | (1 | ) | 401 | ||||||||||||||||||
| Research and development expenses(c) | 125 | (1 | ) | — | — | 124 | |||||||||||||||||||
| Amortization of intangible assets(d) | 39 | (34 | ) | — | — | 5 | |||||||||||||||||||
| Restructuring charges and certain acquisition-related costs | 14 | — | (22 | ) | 8 | — | |||||||||||||||||||
| Other (income)/deductions–net | (55 | ) | — | — | 42 | (13 | ) | ||||||||||||||||||
| Income before provision for taxes on income | 418 | 67 | 22 | (45 | ) | 462 | |||||||||||||||||||
| Provision for taxes on income | 73 | 16 | 4 | (13 | ) | 80 | |||||||||||||||||||
| Net income attributable to Zoetis | 345 | 51 | 18 | (32 | ) | 382 | |||||||||||||||||||
| Earnings per common share attributable to Zoetis–diluted | 0.71 | 0.11 | 0.04 | (0.07 | ) | 0.79 | |||||||||||||||||||
| Quarter Ended December 31, 2017 | |||||||||||||||||||||||||
| GAAP | Purchase | Acquisition- | Certain | Non-GAAP | |||||||||||||||||||||
| Cost of sales(c) | $ | 457 | $ | (2 | ) | $ | — | $ | (1 | ) | $ | 454 | |||||||||||||
| Gross profit | 1,003 | 2 | — | 1 | 1,006 | ||||||||||||||||||||
| Selling, general and administrative expenses(c) | 361 | (1 | ) | — | (1 | ) | 359 | ||||||||||||||||||
| Research and development expenses(c) | 110 | — | — | — | 110 | ||||||||||||||||||||
| Amortization of intangible assets(d) | 23 | (19 | ) | — | — | 4 | |||||||||||||||||||
| Restructuring charges and certain acquisition-related costs | 12 | — | (2 | ) | (10 | ) | — | ||||||||||||||||||
| Other (income)/deductions–net | 17 | — | — | (3 | ) | 14 | |||||||||||||||||||
| Income before provision for taxes on income | 430 | 22 | 2 | 15 | 469 | ||||||||||||||||||||
| Provision for taxes on income | 350 | 21 | — | (242 | ) | 129 | |||||||||||||||||||
| Net income attributable to Zoetis | 81 | 1 | 2 | 257 | 341 | ||||||||||||||||||||
| Earnings per common share attributable to Zoetis–diluted | 0.16 | — | — | 0.53 | 0.69 | ||||||||||||||||||||
Certain amounts may reflect rounding adjustments.
| ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data) | |||||||||||||||||||||||||
| Twelve Months Ended December 31, 2018 | |||||||||||||||||||||||||
| GAAP | Purchase | Acquisition- | Certain | Non-GAAP | |||||||||||||||||||||
| Cost of sales(c) | $ | 1,911 | $ | (27 | ) | $ | — | $ | (8 | ) | $ | 1,876 | |||||||||||||
| Gross profit | 3,914 | 27 | — | 8 | 3,949 | ||||||||||||||||||||
| Selling, general and administrative expenses(c) | 1,484 | (32 | ) | — | (2 | ) | 1,450 | ||||||||||||||||||
| Research and development expenses(c) | 432 | (2 | ) | — | — | 430 | |||||||||||||||||||
| Amortization of intangible assets(d) | 117 | (101 | ) | — | — | 16 | |||||||||||||||||||
| Restructuring charges and certain acquisition-related costs | 68 | — | (63 | ) | (5 | ) | — | ||||||||||||||||||
| Other (income)/deductions–net | (83 | ) | — | — | 58 | (25 | ) | ||||||||||||||||||
| Income before provision for taxes on income | 1,690 | 162 | 63 | (43 | ) | 1,872 | |||||||||||||||||||
| Provision for taxes on income | 266 | 43 | 13 | 29 | 351 | ||||||||||||||||||||
| Net income attributable to Zoetis | 1,428 | 119 | 50 | (72 | ) | 1,525 | |||||||||||||||||||
| Earnings per common share attributable to Zoetis–diluted | 2.93 | 0.24 | 0.10 | (0.14 | ) | 3.13 | |||||||||||||||||||
| Twelve Months Ended December 31, 2017 | |||||||||||||||||||||||||
| GAAP | Purchase | Acquisition- | Certain | Non-GAAP | |||||||||||||||||||||
| Cost of sales(c) | $ | 1,775 | $ | (7 | ) | $ | — | $ | (7 | ) | $ | 1,761 | |||||||||||||
| Gross profit | 3,532 | 7 | — | 7 | 3,546 | ||||||||||||||||||||
| Selling, general and administrative expenses(c) | 1,334 | (5 | ) | — | (4 | ) | 1,325 | ||||||||||||||||||
| Research and development expenses(c) | 382 | (2 | ) | — | — | 380 | |||||||||||||||||||
| Amortization of intangible assets(d) | 91 | (74 | ) | — | — | 17 | |||||||||||||||||||
| Restructuring charges and certain acquisition-related costs | 19 | — | (10 | ) | (9 | ) | — | ||||||||||||||||||
| Other (income)/deductions–net | 6 | — | — | (5 | ) | 1 | |||||||||||||||||||
| Income before provision for taxes on income | 1,525 | 88 | 10 | 25 | 1,648 | ||||||||||||||||||||
| Provision for taxes on income | 663 | 37 | 3 | (238 | ) | 465 | |||||||||||||||||||
| Net income attributable to Zoetis | 864 | 51 | 7 | 263 | 1,185 | ||||||||||||||||||||
| Earnings per common share attributable to Zoetis–diluted | 1.75 | 0.10 | 0.01 | 0.54 | 2.40 | ||||||||||||||||||||
| Certain amounts may reflect rounding adjustments. |
| (a) The consolidated statements of income present the three and twelve months ended December 31, 2018 and 2017. Subsidiaries operating outside the United States are included for the |
| (b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its |
| (c) Exclusive of amortization of intangible assets, except as discussed in footnote (d) below. |
| (d) Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and |
| See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1), (2) and (3). |
| ZOETIS INC. NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars) | |||||||||||||||||
| (1) Income taxes in Purchase accounting adjustments for 2017 includes a provisional tax benefit of $17 million related to the (2) Acquisition-related costs include the following: | |||||||||||||||||
| Fourth Quarter | Full Year | ||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||
| Transaction costs(a) | $ | — | $ | — | $ | 21 | $ | — | |||||||||
| Integration costs(b) | 11 | 2 | 21 | 6 | |||||||||||||
| Restructuring charges(c) | 11 | — | 21 | 4 | |||||||||||||
| Total acquisition-related costs—pre-tax | 22 | 2 | 63 | 10 | |||||||||||||
| Income taxes(d) | 4 | — | 13 | 3 | |||||||||||||
| Total acquisition-related costs—net of tax | $ | 18 | $ | 2 | $ | 50 | $ | 7 | |||||||||
| Certain amounts may reflect rounding adjustments. |
| (a) Represents external costs directly related to acquiring businesses and primarily includes expenditures for banking, legal, accounting and other similar services. |
| (b) Represents external, incremental costs directly related to integrating acquired businesses and primarily includes expenditures for consulting and the integration of |
| (c) Represents employee termination costs related to the 2018 acquisition of Abaxis and the 2017 acquisition of an Irish biologic therapeutics company. |
| (d) Included in Provision for taxes on income. Represents the tax effect of the associated pre-tax acquisition-related amounts, calculated by determining the |
| (3) Certain significant items include the following: |
| Fourth Quarter | Full Year | |||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||||
| Operational efficiency initiative(a) | $ | (1 | ) | $ | 1 | $ | (1 | ) | $ | 5 | ||||||||
| Supply network strategy(a) | 2 | 8 | 10 | 15 | ||||||||||||||
| Other restructuring charges and cost-reduction/productivity initiatives(b) | (4 | ) | 4 | 7 | 4 | |||||||||||||
| Net gain on sale of assets(c) | (42 | ) | — | (42 | ) | — | ||||||||||||
| Stand-up costs(d) | — | 3 | — | 3 | ||||||||||||||
| Other(e) | — | (1 | ) | (17 | ) | (2 | ) | |||||||||||
| Total certain significant items—pre-tax | (45 | ) | 15 | (43 | ) | 25 | ||||||||||||
| Income taxes(f) | (13 | ) | (242 | ) | 29 | (238 | ) | |||||||||||
| Total certain significant items—net of tax | $ | (32 | ) | $ | 257 | $ | (72 | ) | $ | 263 | ||||||||
| Certain amounts may reflect rounding adjustments. |
| (a) Represents consulting fees and product transfer costs, adjustments to inventory reserves and accelerated depreciation included in Cost of sales, consulting fees |
| (b) Represents employee termination costs/(reversals) in Europe as a result of initiatives to better align our organizational structure, included in Restructuring charges |
| (c) Represents a net gain related to the divestiture of certain agribusiness products within our International segment, included in Other (income)/deductions—net. |
| (d) Represents certain nonrecurring costs related to becoming an independent public company, such as the creation of standalone systems and infrastructure, site |
| (e) For 2018, primarily represents a net gain related to the relocation of a manufacturing site in China, included in Other (income)/deductions—net. |
| For 2017, primarily represents costs associated with changes to our operating model in Cost of sales and Selling, general and administrative expenses, and income |
| (f) Included in Provision for taxes on income. Represents the tax effect of the associated pre-tax certain significant items amounts, calculated by determining the |
| For 2018, also includes (i) a net tax benefit of $45 million related to a measurement period adjustment to the one-time mandatory deemed repatriation tax on the |
| For 2017, also includes (i) a provisional net tax charge of $229 million related to the impact of the Tax Cuts and Jobs Act enacted on December 22, 2017, |
| ZOETIS INC. ADJUSTED SELECTED COSTS AND EXPENSES(a) (UNAUDITED) (millions of dollars) | ||||||||||||||||||||||
| Fourth Quarter | % Change | |||||||||||||||||||||
| 2018 | 2017 | Total | Foreign | Operational(b) | ||||||||||||||||||
| Adjusted cost of sales | $ | 526 | $ | 454 | 16 | % | 1% | 15% | ||||||||||||||
| As a percent of revenue | 33.6 | % | 31.1 | % | NA | NA | NA | |||||||||||||||
| Adjusted SG&A expenses | $ | 401 | $ | 359 | 12 | % | (3)% | 15% | ||||||||||||||
| Adjusted R&D expenses | 124 | 110 | 13 | % | (1)% | 14% | ||||||||||||||||
| Adjusted net income attributable to Zoetis | 382 | 341 | 12 | % | (9)% | 21% | ||||||||||||||||
| Full Year | % Change | |||||||||||||||||||||
| 2018 | 2017 | Total | Foreign | Operational(b) | ||||||||||||||||||
| Adjusted cost of sales | $ | 1,876 | $ | 1,761 | 7 | % | 2% | 5% | ||||||||||||||
| As a percent of revenue | 32.2 | % | 33.2 | % | NA | NA | NA | |||||||||||||||
| Adjusted SG&A expenses | $ | 1,450 | $ | 1,325 | 9 | % | —% | 9% | ||||||||||||||
| Adjusted R&D expenses | 430 | 380 | 13 | % | —% | 13% | ||||||||||||||||
| Adjusted net income attributable to Zoetis | 1,525 | 1,185 | 29 | % | (2)% | 31% | ||||||||||||||||
| Certain amounts and percentages may reflect rounding adjustments. |
| (a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net |
| (b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. |
| ZOETIS INC. 2019 GUIDANCE | |||
| Selected Line Items (millions of dollars, except per share amounts) | Full Year 2019 | ||
| Revenue | $6,175 to $6,300 | ||
| Operational growth(a) | 7.5% to 9.5% | ||
| Organic operational growth(b) | 4.5% to 6.5% | ||
| Adjusted cost of sales as a percentage of revenue(c) | 31% to 32% | ||
| Adjusted SG&A expenses(c) | $1,470 to $1,520 | ||
| Adjusted R&D expenses(c) | $445 to $465 | ||
| Adjusted interest expense and other (income)/deductions(c) | Approximately $220 | ||
| Effective tax rate on adjusted income(c) | 20% to 21% | ||
| Adjusted diluted EPS(c) | $3.42 to $3.52 | ||
| Adjusted net income(c) | $1,650 to $1,700 | ||
| Operational growth(a)(d) | 8% to 11% | ||
| Certain significant items and acquisition-related costs(e) | $90 to $120 | ||
| The guidance reflects foreign exchange rates as of late January 2019. |
| Reconciliations of 2019 reported guidance to 2019 adjusted guidance follows: |
| (millions of dollars, except per share amounts) | Reported | Certain significant | Purchase | Adjusted(b) | ||||||||
| Cost of sales as a percentage of revenue | 32.5% - 33.5% | ~ (1.0%) | ~ (0.5%) | 31% - 32% | ||||||||
| SG&A expenses | $1,545 to $1,595 | ($75) | $1,470 to $1,520 | |||||||||
| R&D expenses | $447 to $467 | ($2) | $445 to $465 | |||||||||
| Interest expense and other (income)/deductions | ~ $220 | ~ $220 | ||||||||||
| Effective tax rate | 20% to 21% | 20% to 21% | ||||||||||
| Diluted EPS | $2.83 to $2.99 | $0.15 to $0.22 | $0.37 | $3.42 to $3.52 | ||||||||
| Net income attributable to Zoetis | $1,365 to $1,445 | $75 to $105 | ~ $180 | $1,650 to $1,700 |
| (a) Operational growth (a non-GAAP financial measure) excludes the impact of foreign exchange. |
| (b) Organic operational growth (a non-GAAP financial measure) excludes the impact of the acquisition of Abaxis as well as foreign exchange. |
| (c) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. generally accepted accounting principles (GAAP) net income and |
| (d) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational growth to the most directly comparable GAAP reported |
| (e) Primarily includes certain nonrecurring costs related to the acquisition of Abaxis and other charges. |
| ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) | ||||||||||||||||||||
| Fourth Quarter | % Change | |||||||||||||||||||
| 2018 | 2017 | Total | Foreign | Operational(b) | ||||||||||||||||
| Revenue: | ||||||||||||||||||||
| Livestock | $ | 872 | $ | 891 | (2 | )% | (4)% | 2% | ||||||||||||
| Companion Animal | 664 | 561 | 18 | % | (3)% | 21% | ||||||||||||||
| Contract Manufacturing & Human Health Diagnostics | 28 | 8 | * | * | * | |||||||||||||||
| Total Revenue | $ | 1,564 | $ | 1,460 | 7 | % | (4)% | 11% | ||||||||||||
| U.S. | ||||||||||||||||||||
| Livestock | $ | 384 | $ | 374 | 3 | % | —% | 3% | ||||||||||||
| Companion Animal | 425 | 338 | 26 | % | —% | 26% | ||||||||||||||
| Total U.S. Revenue | $ | 809 | $ | 712 | 14 | % | —% | 14% | ||||||||||||
| International | ||||||||||||||||||||
| Livestock | $ | 488 | $ | 517 | (6 | )% | (8)% | 2% | ||||||||||||
| Companion Animal | 239 | 223 | 7 | % | (7)% | 14% | ||||||||||||||
| Total International Revenue | $ | 727 | $ | 740 | (2 | )% | (7)% | 5% | ||||||||||||
| Livestock: | ||||||||||||||||||||
| Cattle | $ | 525 | $ | 543 | (3 | )% | (4)% | 1% | ||||||||||||
| Swine | 163 | 166 | (2 | )% | (5)% | 3% | ||||||||||||||
| Poultry | 127 | 122 | 4 | % | (4)% | 8% | ||||||||||||||
| Fish | 40 | 39 | 3 | % | (5)% | 8% | ||||||||||||||
| Other | 17 | 21 | (19 | )% | (3)% | (16)% | ||||||||||||||
| Total Livestock Revenue | $ | 872 | $ | 891 | (2 | )% | (4)% | 2% | ||||||||||||
| Companion Animal: | ||||||||||||||||||||
| Dogs and Cats | $ | 613 | $ | 514 | 19 | % | (3)% | 22% | ||||||||||||
| Horses | 51 | 47 | 9 | % | (3)% | 12% | ||||||||||||||
| Total Companion Animal Revenue | $ | 664 | $ | 561 | 18 | % | (3)% | 21% | ||||||||||||
| * Calculation not meaningful. |
| Certain amounts and percentages may reflect rounding adjustments. |
| (a) For a description of each segment, see Zoetis’ most recent Annual Report on Form 10-K. |
| (b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. |
| ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) | ||||||||||||||||||
| Full Year | % Change | |||||||||||||||||
| 2018 | 2017 | Total | Foreign | Operational(b) | ||||||||||||||
| Revenue: | ||||||||||||||||||
| Livestock | $ | 3,154 | $ | 3,037 | 4 | % | —% | 4% | ||||||||||
| Companion Animal | 2,613 | 2,226 | 17 | % | —% | 17% | ||||||||||||
| Contract Manufacturing & Human Health Diagnostics | 58 | 44 | 32 | % | 1% | 31% | ||||||||||||
| Total Revenue | $ | 5,825 | $ | 5,307 | 10 | % | —% | 10% | ||||||||||
| U.S. | ||||||||||||||||||
| Livestock | $ | 1,269 | $ | 1,244 | 2 | % | —% | 2% | ||||||||||
| Companion Animal | 1,608 | 1,376 | 17 | % | —% | 17% | ||||||||||||
| Total U.S. Revenue | $ | 2,877 | $ | 2,620 | 10 | % | —% | 10% | ||||||||||
| International | ||||||||||||||||||
| Livestock | $ | 1,885 | $ | 1,793 | 5 | % | (1)% | 6% | ||||||||||
| Companion Animal | 1,005 | 850 | 18 | % | 1% | 17% | ||||||||||||
| Total International Revenue | $ | 2,890 | $ | 2,643 | 9 | % | —% | 9% | ||||||||||
| Livestock: | ||||||||||||||||||
| Cattle | $ | 1,754 | $ | 1,735 | 1 | % | (1)% | 2% | ||||||||||
| Swine | 663 | 621 | 7 | % | 1% | 6% | ||||||||||||
| Poultry | 522 | 479 | 9 | % | —% | 9% | ||||||||||||
| Fish | 132 | 118 | 12 | % | —% | 12% | ||||||||||||
| Other | 83 | 84 | (1 | )% | 1% | (2)% | ||||||||||||
| Total Livestock Revenue | $ | 3,154 | $ | 3,037 | 4 | % | —% | 4% | ||||||||||
| Companion Animal: | ||||||||||||||||||
| Dogs and Cats | 2,445 | 2,075 | 18 | % | 1% | 17% | ||||||||||||
| Horses | 168 | 151 | 11 | % | 1% | 10% | ||||||||||||
| Total Companion Animal Revenue | $ | 2,613 | $ | 2,226 | 17 | % | —% | 17% | ||||||||||
| * Calculation not meaningful. |
| Certain amounts and percentages may reflect rounding adjustments. |
| (a) For a description of each segment, see Zoetis’ most recent Annual Report on Form 10-K. |
| (b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. |
| ZOETIS INC. CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS (UNAUDITED) (millions of dollars) | |||||||||||||||||||
| Fourth Quarter | % Change | ||||||||||||||||||
| 2018 | 2017 | Total | Foreign | Operational(a) | |||||||||||||||
| Total International | $ | 727.2 | $ | 739.5 | (2 | )% | (7)% | 5% | |||||||||||
| Australia | 36.8 | 41.5 | (11 | )% | (7)% | (4)% | |||||||||||||
| Brazil | 84.6 | 95.2 | (11 | )% | (19)% | 8% | |||||||||||||
| Canada | 64.4 | 61.3 | 5 | % | (5)% | 10% | |||||||||||||
| China | 41.3 | 37.2 | 11 | % | (5)% | 16% | |||||||||||||
| France | 38.3 | 36.3 | 6 | % | (2)% | 8% | |||||||||||||
| Germany | 34.9 | 41.0 | (15 | )% | (2)% | (13)% | |||||||||||||
| Italy | 24.5 | 23.6 | 4 | % | (2)% | 6% | |||||||||||||
| Japan | 34.9 | 36.6 | (5 | )% | (1)% | (4)% | |||||||||||||
| Mexico | 26.2 | 25.5 | 3 | % | (6)% | 9% | |||||||||||||
| Spain | 26.8 | 25.5 | 5 | % | (3)% | 8% | |||||||||||||
| United Kingdom | 46.1 | 44.2 | 4 | % | (2)% | 6% | |||||||||||||
| Other Developed | 95.5 | 99.4 | (4 | )% | (3)% | (1)% | |||||||||||||
| Other Emerging | 172.9 | 172.2 | — | % | (11)% | 11% | |||||||||||||
| Full Year | % Change | ||||||||||||||||||
| 2018 | 2017 | Total | Foreign | Operational(a) | |||||||||||||||
| Total International | $ | 2,889.8 | $ | 2,642.9 | 9 | % | —% | 9% | |||||||||||
| Australia | 188.6 | 175.6 | 7 | % | (2)% | 9% | |||||||||||||
| Brazil | 294.7 | 299.8 | (2 | )% | (13)% | 11% | |||||||||||||
| Canada | 202.8 | 184.4 | 10 | % | 1% | 9% | |||||||||||||
| China | 211.4 | 174.4 | 21 | % | 4% | 17% | |||||||||||||
| France | 129.8 | 121.0 | 7 | % | 5% | 2% | |||||||||||||
| Germany | 146.8 | 137.2 | 7 | % | 6% | 1% | |||||||||||||
| Italy | 104.0 | 88.8 | 17 | % | 6% | 11% | |||||||||||||
| Japan | 149.0 | 137.8 | 8 | % | 2% | 6% | |||||||||||||
| Mexico | 100.0 | 85.8 | 17 | % | —% | 17% | |||||||||||||
| Spain | 109.9 | 92.7 | 19 | % | 7% | 12% | |||||||||||||
| United Kingdom | 181.2 | 149.2 | 21 | % | 5% | 16% | |||||||||||||
| Other Developed | 361.4 | 339.4 | 6 | % | 2% | 4% | |||||||||||||
| Other Emerging | 710.2 | 656.8 | 8 | % | (3)% | 11% | |||||||||||||
| Certain amounts and percentages may reflect rounding adjustments. |
| (a) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. |
| ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) | ||||||||||||||||||||
| Fourth Quarter | % Change | |||||||||||||||||||
| 2018 | 2017 | Total | Foreign | Operational(b) | ||||||||||||||||
| U.S.: | ||||||||||||||||||||
| Revenue | $ | 809 | $ | 712 | 14 | % | —% | 14% | ||||||||||||
| Cost of sales | 175 | 153 | 14 | % | —% | 14% | ||||||||||||||
| Gross profit | 634 | 559 | 13 | % | —% | 13% | ||||||||||||||
| Gross margin | 78.4 | % | 78.5 | % | ||||||||||||||||
| Operating expenses | 128 | 109 | 17 | % | —% | 17% | ||||||||||||||
| Other (income)/deductions | — | (3 | ) | * | * | * | ||||||||||||||
| U.S. Earnings | $ | 506 | $ | 453 | 12 | % | —% | 12% | ||||||||||||
| International: | ||||||||||||||||||||
| Revenue | $ | 727 | $ | 740 | (2 | )% | (7)% | 5% | ||||||||||||
| Cost of sales | 240 | 244 | (2 | )% | (5)% | 3% | ||||||||||||||
| Gross profit | 487 | 496 | (2 | )% | (9)% | 7% | ||||||||||||||
| Gross margin | 67.0 | % | 67.0 | % | ||||||||||||||||
| Operating expenses | 148 | 143 | 3 | % | (7)% | 10% | ||||||||||||||
| Other (income)/deductions | 1 | — | * | * | * | |||||||||||||||
| International Earnings | $ | 338 | $ | 353 | (4 | )% | (9)% | 5% | ||||||||||||
| Total Reportable Segments | $ | 844 | $ | 806 | 5 | % | (4)% | 9% | ||||||||||||
| Other business activities(c) | (90 | ) | (89 | ) | 1 | % | ||||||||||||||
| Reconciling Items: | ||||||||||||||||||||
| Corporate(d) | (196 | ) | (188 | ) | 4 | % | ||||||||||||||
| Purchase accounting adjustments(e) | (67 | ) | (22 | ) | * | |||||||||||||||
| Acquisition-related costs(f) | (22 | ) | (2 | ) | * | |||||||||||||||
| Certain significant items(g) | 45 | (15 | ) | * | ||||||||||||||||
| Other unallocated(h) | (96 | ) | (60 | ) | 60 | % | ||||||||||||||
| Total Earnings(i) | $ | 418 | $ | 430 | (3 | )% | ||||||||||||||
| * Calculation not meaningful |
| Certain amounts and percentages may reflect rounding adjustments. |
| (a) For a description of each segment, see Zoetis’ most recent Annual Report on Form 10-K. |
| (b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. |
| (c) Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business |
| (d) Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments. |
| (e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and |
| (f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs. |
| (g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a |
| (h) Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as procurement costs. |
| (i) Defined as income before provision for taxes on income. |
| ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) | ||||||||||||||||||||
| Full Year | % Change | |||||||||||||||||||
| 2018 | 2017 | Total | Foreign | Operational(b) | ||||||||||||||||
| U.S.: | ||||||||||||||||||||
| Revenue | $ | 2,877 | $ | 2,620 | 10 | % | —% | 10% | ||||||||||||
| Cost of sales | 606 | 565 | 7 | % | —% | 7% | ||||||||||||||
| Gross profit | 2,271 | 2,055 | 11 | % | —% | 11% | ||||||||||||||
| Gross margin | 78.9 | % | 78.4 | % | ||||||||||||||||
| Operating expenses | 456 | 421 | 8 | % | —% | 8% | ||||||||||||||
| Other (income)/deductions | — | (3 | ) | * | * | * | ||||||||||||||
| U.S. Earnings | $ | 1,815 | $ | 1,637 | 11 | % | —% | 11% | ||||||||||||
| International: | ||||||||||||||||||||
| Revenue | $ | 2,890 | $ | 2,643 | 9 | % | —% | 9% | ||||||||||||
| Cost of sales | 929 | 889 | 4 | % | —% | 4% | ||||||||||||||
| Gross profit | 1,961 | 1,754 | 12 | % | —% | 12% | ||||||||||||||
| Gross margin | 67.9 | % | 66.4 | % | ||||||||||||||||
| Operating expenses | 559 | 515 | 9 | % | —% | 9% | ||||||||||||||
| Other (income)/deductions | 3 | (1 | ) | * | * | * | ||||||||||||||
| International Earnings | $ | 1,399 | $ | 1,240 | 13 | % | —% | 13% | ||||||||||||
| Total Reportable Segments | $ | 3,214 | $ | 2,877 | 12 | % | —% | 12% | ||||||||||||
| Other business activities(c) | (337 | ) | (313 | ) | 8 | % | ||||||||||||||
| Reconciling Items: | ||||||||||||||||||||
| Corporate(d) | (666 | ) | (625 | ) | 7 | % | ||||||||||||||
| Purchase accounting adjustments(e) | (162 | ) | (88 | ) | 84 | % | ||||||||||||||
| Acquisition-related costs(f) | (63 | ) | (10 | ) | * | |||||||||||||||
| Certain significant items(g) | 43 | (25 | ) | * | ||||||||||||||||
| Other unallocated(h) | (339 | ) | (291 | ) | 16 | % | ||||||||||||||
| Total Earnings(i) | $ | 1,690 | $ | 1,525 | 11 | % | ||||||||||||||
| * Calculation not meaningful |
| Certain amounts and percentages may reflect rounding adjustments. |
| (a) For a description of each segment, see Zoetis’ most recent Annual Report on Form 10-K. |
| (b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. |
| (c) Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business and human health diagnostics business. |
| (d) Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments. |
| (e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments. |
| (f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs. |
| (g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, costs associated with the operational efficiency initiative and supply network strategy, certain legal and commercial settlements, and the impact of divestiture-related gains and losses. |
| (h) Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as procurement costs. |
| (i) Defined as income before provision for taxes on income. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005421/en/
Contacts
Media Contacts:
Elinore White
1-973-443-2835 (o)
elinore.y.white@zoetis.com
Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com
Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com
Marissa Patel
1-973-443-2996 (o)
marissa.patel@zoetis.com
Source: Zoetis Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190214005421/en
